All patients had received a 1 year or more (4.7 ± 3.3 years) treatment for osteoporosis that included bisphosphonates (n = 61), denosumab (n = 33), romosozumab (n = 14), teriparatide (n = 9), and selective estrogen receptor modulators (n = 5). This evidence concerns the gene ESR1 and osteoporosis.